Computer development of new drugs
DOI:
https://doi.org/10.22201/cuaieed.16076079e.2021.22.6.5Keywords:
drug design, molecular docking, virtual screening, molecular dynamicsAbstract
This article describes the usefulness of computational methods for the identification and design of new compounds for disease treatment. The crucial steps for these methods are described and examples of different drugs of commercial use, designed using these computational strategies, are mentioned.
References
Ashburn, T. T. y Thor, K. B. (2004). Drug repositioning: Identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery, 3, 673-683. https://doi.org/10.1038/nrd1468.
Balbuena-Rebolledo, I., Padilla-Martínez, I. I., Rosales-Hernández, M. C. y Bello, M. (2021). Repurposing fda Drug Compounds against Breast Cancer by Targeting egfr/her2. Pharmaceuticals, 14(8), 791. https://doi.org/10.3390/ph14080791.
Bello, M., Martinez-Archundia, M. y Correa-Basurto, J. (2013). Automated docking for novel drug discovery. Expert Opinion on Drug Discovery, 8(7), 821-834. https://doi.org/10.1517/17460441.2013.794780.
Bello, M., Guadarrama-García, C. y Rodriguez-Fonseca, R.A. (2020). Dissecting the molecular recognition of dual lapatinib derivatives for egfr/her2. J Comput Aided Mol Des, 34(3), 293-303. https://doi.org/10.1007/s10822-019-00270-4.
Miller iii, B. R., McGee Jr, T. D., Swails, J. M., Homeyer, N., Gohlke, H. y Roitberg, A. E. (2012). mmpbsa.py: an efficient program for end-state free energy calculations. Journal of chemical theory and computation, 8(9), 3314-3321. https://doi.org/10.1021/ct300418h.
Lavecchia, A. y di Giovanni, C. (2013). Virtual screening strategies in drug discovery: A critical review. Current Medicinal Chemistry, 20(23), 2839-2860. https://doi.org/10.2174/09298673113209990001.
Li, J., Wang, H., Li, J., Bao, J. y Wu, C. (2016). Discovery of a Potential her2 Inhibitor from Natural Products for the Treatment of her2-Positive Breast Cancer. Int J Mol Sci, 17(7), 1055. https://doi.org/10.3390/ijms17071055.
Moreira-Silva, F., Camilo, V., Gaspar, V., Mano, J.F., Henrique, R., Jerónimo, C. (2020). Repurposing Old Drugs into New Epigenetic Inhibitors: Promising Candidates for Cancer Treatment? Pharmaceutics, 12(5), 410. https://doi.org/10.3390/pharmaceutics12050410.
Murcko, M. A. (1995). Computational methods to predict binding free energy in ligand-receptor complexes. Journal of medicinal chemistry, 38(26), 4953-4967. https://doi.org/10.1021/jm00026a001.
Paul, S. M. y Lewis-Hall, F. (2013). Drugs in search of diseases. Science Translational Medicine, 5(186), 186fs18. https://doi.org/10.1126/scitranslmed.3004452.
Rull, J. A., Quibrera, R., González-Millán, H. y Castañeda Lozano, O. (1969). Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol®): Double blind crossover trial. Diabetologia, 5, 215-218.
Seidel, C, Schnekenburger, M., Dicato, M. y Diederich, M. (2012). Histone deacetylase modulators provided by Mother Nature. Genes Nutr, 7(3), 357-367. https://doi.org/10.1007/s12263-012-0283-9.
Scafuri, B., Bontempo, P., Altucci, L., De Masi, L. y Facchiano, A. (2020). Molecular Docking Simulations on Histone Deacetylases (hdac)-1 and -2 to Investigate the Flavone Binding. Biomedicines, 8(12), 568. https://doi.org/10.3390/biomedicines8120568.
Sixto-López, Y., Gómez-Vidal, J. A., de Pedro, N., Bello, M., Rosales-Hernández, M. C. y Correa-Basurto, J. (2020). Hydroxamic acid derivatives as hdac1, hdac6 and hdac8 inhibitors with antiproliferative activity in cancer cell lines. Sci Rep, 10(10462). https://doi.org/10.1038/s41598-020-67112-4.
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Revista Digital Universitaria es editada por la Universidad Nacional Autónoma de México se distribuye bajo una Licencia Creative Commons Atribución-NoComercial 4.0 Internacional. Basada en una obra en http://revista.unam.mx/.
